I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Roche and Genentech at

ASRS 2025

July 30 - August 02

California, USA / Virtual (Hybrid)

asrs.org

We will be contributing to topics related to

Ophthalmology

Agenda

Medical Materials

03:00 PM

Duration 10mins Long Beach Convention Center

Machine Learning–Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab▼ vs Aflibercept in TENAYA/LUCERNE

Yoshihiro Yonekawa, Lanzetta P, Albrecht T, Harrell E, Hibar D, Lu H, Patel S, Yang M, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Faricimab▼ Real-World Data Support Clinical Trial Data in Patients With Treatment-Naïve nAMD: Results From TENAYA/LUCERNE and FARETINA/FARWIDE

Sara Haug, Avery R, Souied E, Bonine N, Dayal P, Kotecha A, Margaron P, Yang M

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials

Michael Klufas, Gerendas B, Ambresin A, Arevalo J F, Gibson K, Sim D, Yang M

Ophthalmology | Diabetic Macular Edema

Duration 10mins Long Beach Convention Center

Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With nAMD or DME: The VOYAGER Study

Aboobaker S, Schmitz-Valckenberg S, Bailey C, Chaikitmongkol V, Chaudhary V, Chi GC, Downey A, Finger RP, Koh A HC, Ishida S, Lövestam-Adrian M, Parravano M, Luna Pinto JD, Sheth V, Shi B, Souied EH, Uschner D, Guymer R

Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Real-World Outcomes of Faricimab▼ in nAMD From the UK: 18-Month Results From the FARWIDE-nAMD Study

Praveen Patel, Varma D, Talks J, De Salvo G, De Silva S, Gale R, McKibbin M, Chi G, James N, Downey A, Dodds M, Dayal P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Real-World Outcomes of Faricimab▼ in DME From the UK: 1-Year Results From the FARWIDE-DME Study

Ian Pearce, Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L,Kiire C, Chi G, James N, Downey A, Dodds M, Dayal P

Ophthalmology | Diabetic Macular Edema

Duration 10mins Long Beach Convention Center

Association of Early Macular Leakage Resolution With Extended Dosing Intervals in Patients With RVO: A BALATON/COMINO Post Hoc Analysis

Carl Danzig, Bhatt H, Dagincourt N, Pereira L P, Schweitzer J, Thommen J

Ophthalmology | Retinal Vein Occlusion

Duration 10mins Long Beach Convention Center

Real-World Survey on Physician Preferences and Dosing Schedules for Anti-VEGF Therapies in the Treatment of nAMD

Shilpa Gulati, Ko S, Bonine N, Coak E, Mascia D, Li K

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Fluctuations in Pigment Epithelial Detachment Thickness in the Archway Phase 3 Trial of the PDS

Malik D, Brodie F, Graff J, Lai T, Ruiz Medrano J, Priglinger S, Blotner, Gordon A, Holekamp N, Prager, A Heinrich D

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Impact of the Optimization of Surgical Procedure on the Incidence of Endophthalmitis and Associated Outcomes of Patients in PDS Trials

Chang M, Chaudhry N, Campochiaro P, Pieramici D, Regillo C, Bobbala A, Gune S, Jaycock P, Kardatzke D, Prager A, Singh N

Ophthalmology | Diabetic Macular Edema - Diabetic Retinopathy - Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Mitigating Conjunctival Erosions in Patients Treated With the PDS: Surgical Management and Clinical Outcomes

Suan E, Klufas M, Regillo C, Awh C, Gordon A, Blotner S, Prager A, Singh N, Utley S, Gune S

Ophthalmology | Diabetic Macular Edema - Diabetic Retinopathy - Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Clinical Impact of Continuous Drug Delivery via the PDS in Retinal Diseases

Arevalo JF, Graff J, Campochiaro P, Chakravarthy U, Emanuelli A, Gill M, Rachitskaya A, Wirthlin R, Blotner S, Gune S, Singh N

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 10mins Long Beach Convention Center

Real-World Treatment Patterns and Ocular Morbidity in Patients With Uveitic Macular Edema Secondary to Noninfectious Uveitis in the United States

Uchiyama E, Chen L, Dayal P, Pal N, Stoilov I, Mesquida M, Haskova Z, Steeples L

Ophthalmology | Uveitic Macular Edema

05:51 PM

Duration 3mins Long Beach Convention Center

Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab▼ vs Aflibercept From Phase 3 YOSEMITE/RHINE

Murtaza Adam, Vujosevic S, Pollreisz A, Dinah C, Goldberg R, Ip M, Rahimy E, Amador M, Bachmeier I, Gibson K, Maunz A, O'Leary O, Uschner D

Ophthalmology | Diabetic Macular Edema

05:54 PM

Duration 3mins Long Beach Convention Center

Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US

Andres Emanuelli, Amador M, Brown J, Coney J, Cunningham M, Gonzalez L, Huddleston S,Scott A, Milunovich S, Yang M, Lu X-Y

Ophthalmology | Diabetic Macular Edema

05:57 PM

Duration 3mins Long Beach Convention Center

Update on Faricimab▼ for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study

Veeral Sheth, Arshad M. Khanani, Cheryl Jones, Kara Gibson, Timothy Y. Y. Lai, Ian Pearce, Patricio Schlottmann, Dawn A. Sim

Ophthalmology | Diabetic Macular Edema

06:09 PM

Duration 3mins Long Beach Convention Center

Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultrawide Field Images in YOSEMITE/RHINE Phase 3 Studies

Blodi B, Domalpally A, Tang Y, Willis J, Gibson K, Khanani A, Wykoff C, Haskova Z

Ophthalmology | Diabetic Macular Edema

06:38 PM

Duration 3mins Long Beach Convention Center

Impact of PDS in Study Eyes vs Intravitreal Injections in Fellow Eyes in Pagoda Trial Patients With Bilateral Diabetic Macular Edema (DME)

Graff J, Eichenbaum, D, Wirthlin R, Yi-Ting Hsieh, Jason Hsu, Patricia Udaondo, Heinrich D, Gune S, Blotner S, Jones M, Schimpl A, Santhanankrishnan A

Ophthalmology | Diabetic Macular Edema

12:37 AM

Duration 60mins California, USA

Quantitative Ultra-Widefield Fluorescein Angiography for the Assessment of Novel Biomarkers of Vascular Stability With Faricimab▼ in YOSEMITE/RHINE

Karen Matar, Justis Ehlers, Indurkar A, Della Vecchia L, Amine R, Mamone J, Tang A, Gibson K, Dagincourt N, Mar F, Amador M, Warter A, Sim D

Ophthalmology | Diabetic Macular Edema

Duration 60mins California, USA

Zifibancimig Administered via Intravitreal Injection and the Port Delivery Platform in Patients With nAMD: Rationale and Design of the Burgundy Study

Wolfe J, Haug S, Dhoot D, Kim J, Kwong M, Callaway N, Orduna J, Steiert B, Wollenhaupt M, Wentzel C

Ophthalmology | Neovascular Age Related Macular Degeneration

05:35 PM

Duration 3mins Long Beach Convention Center

Baseline and Early Treatment Response Variables Associated With Faricimab▼ Durability in Treatment-Naïve nAMD: TENAYA/LUCERNE Post Hoc Analyses

Ben Bakall, Tan C, Gallego-Pinazo R, Koh A, Pitcher J, Yang M, Patel S, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

05:44 PM

Duration 3mins Long Beach Convention Center

Indirect Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in DME and nAMD

Nik London, Keane P, Holekamp N, Leng T,Siedlecki J, Mar F, Gibson K, Margaron P, Buehrer C, Tabano D

Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

05:47 PM

Duration 3mins Long Beach Convention Center

Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS

Kitchens J, Andrea-Thanei G, Blotner S, Gune S, Rabena M, Singh N

Ophthalmology | Neovascular Age Related Macular Degeneration

Coming soon